tolmetin has been researched along with HbS Disease in 7 studies
Tolmetin: A non-steroidal anti-inflammatory agent (ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL) similar in mode of action to INDOMETHACIN.
tolmetin : A monocarboxylic acid that is (1-methylpyrrol-2-yl)acetic acid substituted at position 5 on the pyrrole ring by a 4-methylbenzoyl group. Used in the form of its sodium salt dihydrate as a nonselective nonsteroidal anti-inflammatory drug.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients receiving ketorolac and those receiving placebo were of similar age, weight, gender, number of prior ED visits, number of prior hospital admissions, duration of pain prior to presentation, and initial pain score." | 9.09 | Effect of ketorolac in pediatric sickle cell vaso-occlusive pain crisis. ( Givens, TG; Hardwick, WE; King, WD; Lawley, D; Monroe, KW, 1999) |
| "To determine if a single dose of intramuscular ketorolac given on presentation to the emergency department has a narcotic-sparing effect in adult patients with sickle cell vaso-occlusive crisis pain." | 9.07 | Ketorolac for sickle cell vaso-occlusive crisis pain in the emergency department: lack of a narcotic-sparing effect. ( Mitchell, TR; Norris, RL; Wright, SW, 1992) |
| "Patients receiving ketorolac and those receiving placebo were of similar age, weight, gender, number of prior ED visits, number of prior hospital admissions, duration of pain prior to presentation, and initial pain score." | 5.09 | Effect of ketorolac in pediatric sickle cell vaso-occlusive pain crisis. ( Givens, TG; Hardwick, WE; King, WD; Lawley, D; Monroe, KW, 1999) |
| "To determine if a single dose of intramuscular ketorolac given on presentation to the emergency department has a narcotic-sparing effect in adult patients with sickle cell vaso-occlusive crisis pain." | 5.07 | Ketorolac for sickle cell vaso-occlusive crisis pain in the emergency department: lack of a narcotic-sparing effect. ( Mitchell, TR; Norris, RL; Wright, SW, 1992) |
| "The gene for sickle cell disease is carried by 8% of the African-American population in the United States." | 1.28 | Sickle cell vaso-occlusive pain crisis in adults: alternative strategies for management in the emergency department. ( Pollack, CV; Sanders, DY; Severance, HW, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Perlin, E | 1 |
| Finke, H | 1 |
| Castro, O | 1 |
| Rana, S | 1 |
| Pittman, J | 1 |
| Burt, R | 1 |
| Ruff, C | 1 |
| McHugh, D | 1 |
| Richardson, P | 1 |
| Steingart, R | 1 |
| Simckes, AM | 1 |
| Chen, SS | 1 |
| Osorio, AV | 1 |
| Garola, RE | 1 |
| Woods, GM | 1 |
| Hardwick, WE | 1 |
| Givens, TG | 1 |
| Monroe, KW | 1 |
| King, WD | 1 |
| Lawley, D | 1 |
| Sanders, DY | 1 |
| Severance, HW | 1 |
| Pollack, CV | 1 |
| Wright, SW | 1 |
| Norris, RL | 1 |
| Mitchell, TR | 1 |
| Goodman, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis[NCT00094887] | Phase 2 | 150 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Length of hospitalization is defined as the length of time from admission to discharge order (NCT00094887)
Timeframe: within 40 days
| Intervention | Days (Median) |
|---|---|
| Inhaled Nitric Oxide | 4.06 |
| Placebo | 3.11 |
(NCT00094887)
Timeframe: within 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Nitric Oxide | 5 |
| Placebo | 7 |
Number of participants who required a blood transfusion before discharge because of acute chest syndrome/pneumonia (NCT00094887)
Timeframe: within 40 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Nitric Oxide | 8 |
| Placebo | 7 |
"VOC resolution was defined by all of the following conditions:~Pain relief - Visual Analog Scale (VAS) pain scores of 6 or less, (6 as worst and 0 as best)~Freedom from parenteral narcotic use,~Ability to walk unless the subject was not able to walk for any reason other than acute VOC prior to the onset of crisis,~Subject and/or family's belief that the painful crisis could be managed at home with or without oral analgesic use, and the physician concurred with that assessment." (NCT00094887)
Timeframe: within 30 days
| Intervention | Hours (Median) |
|---|---|
| Inhaled Nitric Oxide | 61.83 |
| Placebo | 55.16 |
The number of participants readmitted to the hospital for any reason within 30 days after discharge (NCT00094887)
Timeframe: during first 24 hours and during 30 day follow-up
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| during first 24 hours | during 30-day follow-up | |
| Inhaled Nitric Oxide | 0 | 9 |
| Placebo | 0 | 17 |
The total dose (mg) of opioid medications received during the trial (NCT00094887)
Timeframe: within 8 hours and within 40 days
| Intervention | mg (Median) | |
|---|---|---|
| within 8 hours | within 40 days | |
| Inhaled Nitric Oxide | 16.25 | 153.75 |
| Placebo | 17.25 | 211.37 |
3 trials available for tolmetin and HbS Disease
| Article | Year |
|---|---|
Enhancement of pain control with ketorolac tromethamine in patients with sickle cell vaso-occlusive crisis.
Topics: Adult; Analgesics; Anemia, Sickle Cell; Constriction, Pathologic; Digestive System Diseases; Double- | 1994 |
Effect of ketorolac in pediatric sickle cell vaso-occlusive pain crisis.
Topics: Adolescent; Adult; Analgesics, Non-Narcotic; Anemia, Sickle Cell; Blood Vessels; Child; Double-Blind | 1999 |
Ketorolac for sickle cell vaso-occlusive crisis pain in the emergency department: lack of a narcotic-sparing effect.
Topics: Acute Disease; Adult; Analgesics; Anemia, Sickle Cell; Double-Blind Method; Emergencies; Female; Hum | 1992 |
4 other studies available for tolmetin and HbS Disease
| Article | Year |
|---|---|
Meperidine and ketorolac in the treatment of painful sickle cell crisis.
Topics: Analgesics; Anemia, Sickle Cell; Humans; Ketorolac; Meperidine; Pain; Tolmetin | 1993 |
Ketorolac-induced irreversible renal failure in sickle cell disease: a case report.
Topics: Adolescent; Anemia, Sickle Cell; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Ketorolac; | 1999 |
Sickle cell vaso-occlusive pain crisis in adults: alternative strategies for management in the emergency department.
Topics: Acetaminophen; Adolescent; Adult; Amitriptyline; Analgesics; Anemia, Sickle Cell; Anti-Inflammatory | 1992 |
Use of ketorolac in sickle-cell disease and vaso-occlusive crisis.
Topics: Adult; Anemia, Sickle Cell; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Ketorolac; Pain | 1991 |